The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IS EFFECTIVE IN THE TREATMENT OF SKIN PLAQUES1

Significantly more patients achieved PASI-75 vs placebo at week 161,a,b

Created with Highcharts 8.0.4Week 16Patients Achieving PASI-75 (%)OTEZLA 30 mg BID (n = 562)Placebo (n = 282)01020304050
5%
33%
PSO-Skin-chart
Man sitting at a table

aESTEEM 1 study. Full analysis set, LOCF.

bP < 0.0001.

Response was maintained with OTEZLA through week 321

See the OTEZLA difference

Real patients, real pictures.*

Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with psoriasis who achieved a 75% decrease in PASI after 16 weeks on OTEZLA®. Please see full Important Safety Information.

Week 16 PASI-75 result

Individual results may vary.

*Actual real-world OTEZLA patient. Property of Amgen Inc.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index.

OTEZLA SIGNIFICANTLY IMPROVES SKIN PLAQUES IN BIOLOGIC-NAÏVE PATIENTS2†

Significant PASI-75 response maintained over 2 years2,a

 
Significant_PASI-75_response_maintained_over_2_years_trans_resized
Older man in front of his bicycle shop

aLIBERATE study. ITT, LOCF.

bP <0.0001, OTEZLA vs placebo.

cIncludes patients who entered and were treated in the OTEZLA extension phase.

Response was maintained with OTEZLA for up to 2 years in biologic-naïve patients

See the OTEZLA difference

Real patients, real pictures.

Actual patient with skin plaque before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with skin plaques who achieved an 80% decrease in PASI after 16 weeks on OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16 PASI-80 result

Individual results may vary.

In biologic-naïve patients with moderate to severe plaque psoriasis.

Actual real-world OTEZLA patient. Property of Amgen Inc.

ITT, intent to treat; LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis.

References:

  1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
  2. Reich K, Goodfield, M, Green L, et al. Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 on a phase 3b study. Presented at: the 2017 ACR/ARHP Annual Meeting: November 3-8, 2017; San Diego, CA.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.